Roth Capital Partners reinitiated coverage of Savara (NASDAQ:SVRA) with a “buy” rating and $40 price target. The stock closed at $9.24 on Sept. 26.Read More
Leerink initiated coverage of Dova Pharmaceuticals (NASDAQ:DOVA) with a “market perform” rating and a $24 price target. The stock closed at $22.75 on July 21.Read More
Profound Medical (OTCQX:PRFMF; TSXV:PRN) has agreed to expand an existing collaboration with Royal Philips (NYSE:PHG; AEX:PHIA) and acquire Philips’ Sonalleve MR-HIFU business, establishing Profound as a market leader in magnetic resonance (MR) ultrasound ablation therapy.Read More
Maxim Group lowered its price target for Omeros (NASDAQ:OMER) to $19 from $30, citing a higher risk value from its three valuation models. The stock closed at $13.38 on Tuesday.Read More
IntelGenx (OTCQX:IGXT; TSX-V:IGX) has sold its royalty on future sales of Forfivo XL to SWK Holdings for $6-million.
Forfivo XL (bupropion extended release) is the first 450-milligram bupropion hydrogen chloride tablet indicated for major depressive disorder approved by the FDA. Patent protection for Forfivo XL in the U.S. expires in 2027, with an authorized generic entering the market in January 2018.Read More
Maxim Group downgraded Radius Health (NASDAQ:RDUS) to “sell” from “hold” with a $24 price target. The stock closed at $50.55 on Thursday.
“At the current valuation, we believe that Radius is back to an overvalued state,” writes analyst Jason McCarthy.Read More
Cellect Biotechnology (NASDAQ:APOP; TASE:CLBD) priced an initial public offering in the U.S. of 1,292,308 American Depository Shares (ADSs) and warrants to purchase up to 969,231 ADSs.Read More
Dipexium Pharmaceuticals (NASDAQ:DPRX) and Tandem Diabetes (NASDAQ:TNDM) have made Feltl & Co.’s Best Ideas list for the second half this year.
Analyst Ben Haynor writes that top-line data for Dipexium’s two Phase 3 studies should be released in the next six-to-10 weeks, “which we believe will be positive,” based on trials conducted by Magainin Pharmaceuticals in the late 1990s and the design of Dipexium’s studies, which compare Locilex versus placebo cream.Read More
The first 10 patients received treatment last week with Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant of buprenorphine, following FDA approval on May 26.
ProbuphineProbuphine was developed using Titan’s long-term, continuous drug delivery platform, ProNeura, for the maintenance treatment of opioid dependence.Read More
The FDA has granted orphan drug designation to Anavex Life Sciences’ (NASDAQ:AVXL) ANAVEX 2-73 for the treatment of Rett syndrome.
In a statement, Christopher Missling, president and CEO, said orphan drug designation marks the first U.S. movement for ANAVEX 2-73.Read More
Profound Medical (TSX-V:PRN) has received investigational device exemption (IDE) approval from the FDA for a multicenter pivotal clinical trial to evaluate the efficacy of the TULSA-PRO System in patients with localized prostate cancer.
TULSA-PRO, which has received CE Mark in Europe, combines real-time MRI with transurethral robotically-driven ultrasound and closed-loop thermal feedback control, providing a highly precise prostate treatment tailored to patient-specific anatomy.Read More
Roth Capital Partners has raised its price target for Celator Pharmaceuticals (NASDAQ:CPXX) to $26 from $22, after the company’s Vyxeos drug candidate received breakthrough therapy designation from the FDA. The stock closed at $15.07 on Wednesday
“This is an important next step for Vyxeos on the path to what we believe is likely approval,” writes analyst Joseph Pantginis.Read More
Closely-held BioSight has closed an investment of $13-million led by Mori Arkin’s pharmaceutical investment firm, Arkin Holdings, and the U.S.-based venture firm, Primera Capital.
Proceeds will be used for a multi-center, Phase 2b clinical trial with the company’s lead product, Astarabine, for the treatment of acute myeloid leukemia (AML).Read More
Rodman & Renshaw has initiated coverage of Presbia PLC (NASDAQ:LENS) with the “buy” rating and 18-month price target of $14. The stock closed at $3.90 on Tuesday.
Presbia has a novel corneal inlay product, the Flexivue Microlens, aimed at treating presbyopia, or nearsightedness.Read More
CNBC has highlighted Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine six-month implant of buprenorphine in a feature about the treatment of opioid addiction and the crisis of fatal overdoses in the U.S.
The feature discusses the potential benefits of an implant, compared with current sublingual versions of buprenorphine, and the relatively low percentage of doctors authorized to write prescriptions for buprenorphine.Read More
First quarter revenue for TearLab (NASDAQ:TEAR; TSX:TLB) rose 25% to $6.8-million from $5.4-million a year ago.
A net total of 257 TearLab Osmolarity Systems were added in the first quarter of 2016, of which 167 were under the company’s new Flex program and 61 were purchased outside of the U.S.Read More
Profound Medical (TSX-V:PRN) has made the first sale of its TULSA-PRO device to ResoFus Alomar in Barcelona, Spain.
Profound’s novel technology combines real-time magnetic resonance imaging with transurethral robotically driven ultrasound and closed-loop thermal feedback control, providing a highly precise treatment tailored to patient-specific anatomy and pathology.Read More
BTIG Research has raised its price target for Cerus (NASDAQ:CERS) to $10 from $8, saying the progress made by the company has “exceeded even our bullish expectations.” The stock closed at $6.65 on Thursday.
Cerus is a biomedical products company focused on the field of blood safety.Read More
GMP Securities has initiated coverage of Profound Medical (TSX-V:PRN) with a “speculative buy” rating and price target of $2. The stock closed at $1.50 on Monday.
The company is focused on developing and commercializing an innovative therapy for the ablation of prostate cancer tissue, using real-time MRI to greatly improve accuracy, while reducing side effects.Read More
H.C. Wainwright has initiated coverage of BioPharmX (NYSE MKT:BPMX) with a “buy” rating and $3 price target. The stock closed at 99 cents on Wednesday.
BioPharmX’s lead product is Violet for the treatment of fibrocystic breast condition (FBC). It was launched in early 2015 and is currently sold over-the-counter in over 7,500 pharmacies in the U.S.Read More